19 December 2012 | News | By BioSpectrum Bureau
Singapore: NuVasive, a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, has received Japan's approval of the CoRoent Large Impacted and CoRoent Large Tapered titanium alloy implants.
The implants are used in posterior spine fusion procedures and are NuVasive's first two interbody fusion cages to be approved in Japan. The approvals further the company's ability to participate in the world's second largest spine market with certain cervical solutions and a comprehensive posterior product offering, which have already been cleared for use.
"This is an exciting stepping stone for NuVasive. For several years, we have been thoughtfully laying the groundwork and making the investments to support a direct operation in Japan, a market estimated to be close to $400 million in size. We are proud to see all of those efforts coming to fruition so that our revenue ramp can begin in earnest at the start of the first quarter. We look forward to the opportunity to introduce Japanese surgeons and patients to NuVasive; first to our game changing portfolio of cervical and posterior thoraco-lumbar solutions, and then, upon further regulatory approval, to our unique lateral XLIF solution," said Mr Alex Lukianov, chairman and CEO of NuVasive.